Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Torrey

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical & Translational Immunology|February 23, 2016
Treg activation defect in type 1 diabetes: correction with TNFR2 agonismYoshiaki Okubo, Heather Torrey, John Butterworth, et al.
Science Signaling|December 9, 2020
A novel TNFR2 agonist antibody expands highly potent regulatory T cellsHeather Torrey, Willem M Kühtreiber, Yoshiaki Okubo, et al.
Journal of Leukocyte Biology|March 24, 2020
Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificityMichael Yang, Lisa Tran, Heather Torrey, et al.
Science Signaling|January 19, 2017
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated TregsHeather Torrey, John Butterworth, Toshiyuki Mera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II TrialOliver Dorigo, Amit M Oza, Tanja Pejovic, et al.
Chemistry & Biology|April 2, 2014
Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2Ekaterina Gavrish, Clarissa S Sit, Shugeng Cao, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical & Translational Immunology|February 23, 2016
Treg activation defect in type 1 diabetes: correction with TNFR2 agonismYoshiaki Okubo, Heather Torrey, John Butterworth, et al.
Science Signaling|December 9, 2020
A novel TNFR2 agonist antibody expands highly potent regulatory T cellsHeather Torrey, Willem M Kühtreiber, Yoshiaki Okubo, et al.
Journal of Leukocyte Biology|March 24, 2020
Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificityMichael Yang, Lisa Tran, Heather Torrey, et al.
Science Signaling|January 19, 2017
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated TregsHeather Torrey, John Butterworth, Toshiyuki Mera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2023
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II TrialOliver Dorigo, Amit M Oza, Tanja Pejovic, et al.
Chemistry & Biology|April 2, 2014
Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2Ekaterina Gavrish, Clarissa S Sit, Shugeng Cao, et al.
Pageof 1